Cystic fibrosis on the African continent

Genetics in Medicine

Volumn 18, Issue 7, 2016, Pages 653-662

  Stewart, Cheryl ^a   Pepper, Michael S ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Africa; cystic fibrosis; molecular epidemiology

Indexed keywords

AFRICA; ALGERIA; CAMEROON; CHROMOSOME ANALYSIS; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; EGYPT; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; LIBYAN ARAB JAMAHIRIYA; MOROCCO; NAMIBIA; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; RWANDA; SENEGAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTH AFRICA; SUDAN; SURVIVAL; TUNISIA; ZIMBABWE; BLACK PERSON; GENETIC PREDISPOSITION; GENETICS; MUTATION;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; CYSTIC FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PUBLIC HEALTH;

EID: 84977118035     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.157     Document Type: Review

References (74)

1. Hodson M, Bush A, Geddes D, eds. Cystic Fibrosis. 3rd edn. CRC Press: Boca Raton, FL, 2007
2. Goldman A, Graf C, Ramsay M, Leisegang F, Westwood AT. Molecular diagnosis of cystic fibrosis in South African populations. S Afr Med J 2003;93:518-519
3. Ikpa PT, Bijvelds MJ, de Jonge HR. Cystic fibrosis: toward personalized therapies. Int J Biochem Cell Biol 2014;52:192-200
4. Westwood T, Henderson B, Ramsay M; Medical and Scientific Advisory Committee of the South African Cystic Fibrosis Association. Diagnosing cystic fibrosis in South Africa. S Afr Med J 2006;96:304-306
5. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073
6. Amin R, Ratjen F. Emerging drugs for cystic fibrosis. Expert Opin Emerg Drugs 2014;19:143-155
7. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 2015;145:19-34
8. Snouwaert JN, Brigman KK, Latour AM, et al. An animal model for cystic fibrosis made by gene targeting. Science 1992;257:1083-1088
9. The Molecular Genetic Epidemiology of Cystic Fibrosis. World Health Organization: Genoa, Switzerland, 2002
10. Grove SS. Fibrocystic disease of the pancreas in the Bantu. S Afr J Lab Clin Med 1959;5:113-119
11. Levin SE, Blumberg H, Zamit R, Schmaman A, Wagstaff L. Mucoviscidosis (cystic fibrosis of the pancreas) in Bantu twin neonates. S Afr Med J 1967;41:482-485
12. Wang SS, O'Leary LA, Fitzsimmons SC, Khoury MJ. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002;141: 804-810
13. Grosse SD, Boyle CA, Botkin JR, et al.; CDC. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53(RR-13):1-36
14. Mutesa L, Bours V. Diagnostic challenges of cystic fibrosis in patients of African origin. J Trop Pediatr 2009;55:281-286
15. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23:545-549
16. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994;331:974-980
17. Goldman A, Labrum R, Claustres M, et al. The molecular basis of cystic fibrosis in South Africa. Clin Genet 2001;59:37-41
18. Ibrahim SA, Elmola MAF, Karrar ZA, et al. 2014. Cystic fibrosis in Sudanese children: first report of 35 cases. Sudan J Pediatr 2014;14:39-44
19. Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. Hum Mutat 1994;4:167-177
20. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002;19:575-606
21. Castellani C, Conway S, Smyth AR, Stern M, Elborn JS. Standards of Care for Cystic Fibrosis ten years later. J Cyst Fibros 2014;13 Suppl 1:S1-S2
22. Kerem E, Conway S, Elborn S, Heijerman H; Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005;4:7-26
23. Kerem E, Webb AK. European Cystic Fibrosis Society Standards of Care: a road map to improve CF outcome. J Cyst Fibros 2014;13:357-358
24. Stern M, Bertrand DP, Bignamini E, et al. European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. J Cyst Fibros 2014;13 Suppl 1:S43-S59
25. Sheppard DN. The European cystic fibrosis patient registry: the power of sharing data. J Cyst Fibros 2010;9 Suppl 2:S1-S2
26. Cystic Fibrosis Foundation-Care Center Network. 2015. http://www.cff.org/ LivingWithCF/CareCenterNetwork/. Accessed February 2, 2015
27. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 2014;161:233-241
28. Cystic Fibrosis Canada-Annual Report of The Canadian Cystic Fibrosis Registry. 2012. http://www.cysticfibrosis.ca/wp-content/uploads/2014/03/Canadian-CFRegistry-English-FINAL-FOR-WEB1.pdf. Accessed 3 February 2015
29. Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012;129:e348-e355
30. Australian Cystic Fibrosis Data Registry-15th Annual Report from the Australian Cystic Fibrosis Data Registry. 2012. http://www.cysticfibrosis.org. au/media/wysiwyg/CF-Australia/medical-documents/ACFDR-2012/ACFDR- Annual-Report-2012r.pdf. Accessed 3 February 2015
31. Westwood ATR. The prognosis of cystic fibrosis in South Africa: a 33 year study. J Cyst Fibros 2008;7:458
32. Saadallah AA, Rashed MS. Newborn screening: experiences in the Middle East and North Africa. J Inherit Metab Dis 2007;30:482-489
33. South African Cystic Fibrosis Association-Medication. 2015. http://www. sacfa.org.za/about.aspr=&spage=9. Accessed 25 July 2014
34. Statistics South Africa-Census 2011. http://www.statssa.gov.za/publications/ P03014/P030142011.pdf. Accessed 25 July 2014
35. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy 2015;119:964-979
36. van Gool K, Norman R, Delatycki MB, Hall J, Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health 2013;16:345-355
37. Masekela R, Zampoli M, Westwood AT, et al. Phenotypic expression of the 3120+1G>A mutation in non-Caucasian children with cystic fibrosis in South Africa. J Cyst Fibros 2013;12:363-366
38. de Prada Merino A, Butschi FN, Bouchardy I, et al. [R74W;R1070W;D1270N]: a new complex allele responsible for cystic fibrosis. J Cyst Fibros 2010;9: 447-449
39. Ratbi I, Genin E, Legendre M, et al. Cystic fibrosis carrier frequency and estimated prevalence of the disease in Morocco. J Cyst Fibros 2008;7:440-443
40. Quint A, Lerer I, Sagi M, Abeliovich D. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. Am J Med Genet A 2005;136:246-248
41. Boudaya M, Fredj SH, Haj RB, et al. Cystic fibrosis transmembrane conductance regulator mutations and polymorphisms associated with congenital bilateral absence of vas deferens in a restricted group of patients from North Africa. Ann Hum Biol 2012;39:76-79
42. Loumi O, Baghriche M, Delpech M, Kaplan JC, Bienvenu T. Analysis of the complete coding region of the CFTR gene in ten Algerian cystic fibrosis families. Hum Hered 1999;49:81-84
43. Lucotte G, Barre E, Berriche S. Frequency of the cystic fibrosis mutation delta F508 in Algeria. Hum Genet 1991;87:759
44. Hadj Fredj S, Boudaya M, Oueslati S, et al. New frameshift CF mutation 3729delAinsTCT in a Tunisian cystic fibrosis patient. J Genet 2013;92:81-83
45. Fredj SH, Messaoud T, Templin C, des Georges M, Fattoum S, Claustres M. Cystic fibrosis transmembrane conductance regulator mutation spectrum in patients with cystic fibrosis in Tunisia. Genet Test Mol Biomarkers 2009;13:577-581
46. Messaoud T, Fredj SBH, Bibi A, Elion J, Ferec C, Fattoum S. Epidemiologie moleculaire de la mucoviscidose en Tunisie. Ann Biol Clin 2005;63:s69-70
47. Hadj Fredj S, Fattoum S, Chabchoub A, Messaoud T. First report of cystic fibrosis mutations in Libyan cystic fibrosis patients. Ann Hum Biol 2011;38: 561-563
48. El-Seedy A, Pasquet M-C, Shafiek H, El-Komy M, Kitzis A, Ladeveze V. Cystic fibrosis in Egypt: new mutational detection of the CFTR gene in patients from Alexandria, northern Egypt. J Cyst Fibros 2012;12:S53
49. Naguib ML, Schrijver I, Gardner P, et al. Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis. J Cyst Fibros 2007;6:111-116
50. Lissens W, Mahmoud KZ, El-Gindi E, et al. Molecular analysis of the cystic fibrosis gene reveals a high frequency of the intron 8 splice variant 5T in Egyptian males with congenital bilateral absence of the vas deferens. Mol Hum Reprod 1999;5:10-13
51. Mutesa L, Azad AK, Verhaeghe C, et al. Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants. Chest 2009;135:1233-1242
52. Feuillet-Fieux MN, Ferrec M, Gigarel N, et al. Novel CFTR mutations in black cystic fibrosis patients. Clin Genet 2004;65:284-287
53. Ghanem N, Costes B, Girodon E, Martin J, Fanen P, Goossens M. Identification of eight mutations and three sequence variations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1994;21:434-436
54. Cystic Fibrosis Genetic Analysis Consortium. Worldwide survey of the F508 mutation-report from the Cystic Fibrosis Genetic Analysis Consortium. Am J Hum Genet 1990;47:354-359
55. des Georges M, Guittard C, Templin C, et al. WGA allows the molecular characterization of a novel large CFTR rearrangement in a black South African cystic fibrosis patient. J Mol Diagn 2008;10:544-548
56. De Carvalho CL, Ramsay M. CFTR structural rearrangements are not a major mutational mechanism in black and coloured southern African patients with cystic fibrosis. S Afr Med J 2009;99:724
57. Westwood T, Brown R. Cystic fibrosis in black patients: Western Cape experiences. S Afr Med J 2006;96:288-289
58. Padoa C, Goldman A, Jenkins T, Ramsay M. Cystic fibrosis carrier frequencies in populations of African origin. J Med Genet 1999;36:41-44
59. Carles S, Desgeorges M, Goldman A, et al. First report of CFTR mutations in black cystic fibrosis patients of southern African origin. J Med Genet 1996;33:802-804
60. Herbert JS, Retief AE. The frequency of the delta F508 mutation in the cystic fibrosis genes of 71 unrelated South African cystic fibrosis patients. S Afr Med J 1992;82:13-15
61. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013;45:1160-1167
62. Aznarez I, Chan EM, Zielenski J, Blencowe BJ, Tsui LC. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet 2003;12:2031-2040
63. Statistics South Africa. Mid-year population estimates, 2015. http://www. statssa.gov.za/publications/P0302/P03022015.pdf. Accessed 28 July 2015
64. Community Genetics Services. World Health Organization: Geneva, Switzerland, 2010
65. Li W, Sun L, Corey M, et al. Understanding the population structure of North American patients with cystic fibrosis. Clin Genet 2011;79:136-146
66. Gurdasani D, Carstensen T, Tekola-Ayele F, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature 2015;517:327-332
67. Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002;27:619-627
68. Tishkoff SA, Kidd KK. Implications of biogeography of human populations for 'race' and medicine. Nat Genet 2004;36(11 suppl):S21-S27
69. Reed FA, Tishkoff SA. African human diversity, origins and migrations. Curr Opin Genet Dev 2006;16:597-605
70. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008;9:403-433
71. Services for the Prevention and Management of Genetic Disorders and Birth Defects in Developing Countries. World Health Organization: Geneva, Switzerland, 1999
72. Community Approaches to the Control of Hereditary Diseases: Report of a WHO Expert Advisory Group. World Health Organization: Geneva, Switzerland, 1985
73. Sixty-Third World Health Assembly WHA63.17: Birth Defects. World Health Organization: Geneva, Switzerland, 2010
74. United Nations Convention on the Rights of the Child. http://www. ohchr.org/EN/ProfessionalInterest/Pages/CRC.aspx. Accessed 6 August 2015.